Clinical Cancer Research Formatting Requirements: Complete Author Guide

Clinical Cancer Research is not just asking for a tidy oncology manuscript. Editors consistently screen for a translational package: the abstract headings, Translational Relevance statement, endpoint reporting, and patient-facing logic all have to tell the same story. The failure pattern is a paper that looks clinically formatted but still reads like basic cancer biology with a thin patient-care paragraph attached.

AACR describes these limits as article size recommendations that are not enforced for initial submissions and do not affect the assessment of the manuscript. Its style page adds that authors who substantially exceed the word limit for the article type may have the manuscript returned.

AACR's word counts exclude the cover page, abstract, methods section, tables, and references. AACR's FAQ confirms that the methods section is left out when manuscript length is calculated for its journals.

Research Briefs are designed for concise translational studies that make a single, clear point. They're listed at 2,500 words, 4 tables and/or figures and 20 references, and they still require the Translational Relevance statement.

This is the single most important formatting element that distinguishes Clinical Cancer Research from other oncology journals. Every Article and Research Brief must include a Translational Relevance statement of 120 to 150 words (the general AACR style page says 150 words, so the publisher's documents differ slightly).

What the Translational Relevance statement should include:

• How the study connects basic science to clinical application (or vice versa)

• Why the findings matter for patients or clinical practice

• What the next step toward clinical translation would be

• Whether the work informs biomarker development, therapeutic strategy, or disease understanding

Example structure:

"This study demonstrates that the specific finding in [patient population or model]. These results suggest that [biomarker/target/mechanism] could be used to [clinical application: patient selection, treatment response prediction, new therapeutic approach]. If validated in prospective trials, this approach could the specific clinical impact. Our findings provide the rationale for [next translational step]."

Common mistakes:

• Restating the abstract instead of focusing on translational implications

• Being too vague ("these findings may have clinical implications")

• Exceeding 150 words

• Omitting it entirely

In the manuscript, AACR asks for the statement on a page between the title page and the abstract. Write it carefully because it signals to editors that your paper fits Clinical Cancer Research's translational mission.

AACR lists a structured abstract of 250 words for Articles and Research Briefs. Its author instructions do not name the section headings. Abstracts in recent Clinical Cancer Research articles use these headings:

• Purpose: why this study was done

• Experimental Design: how the study was conducted (clinical studies use "Patients and Methods")

• Results: specific findings with quantitative data

• Conclusions: what the findings mean for the field

Note that published Clinical Cancer Research abstracts use "Purpose" and "Experimental Design" or "Patients and Methods" rather than the more common "Background" and "Methods."

The Results section should contain specific data: response rates, hazard ratios, p-values, fold changes. "We found that the drug was effective" is not acceptable. "Patients receiving combination therapy had an objective response rate of 42% (95% CI, 28-57%) compared with 18% for monotherapy (P = 0.003)" is what the editors expect.

Clinical Cancer Research allows up to 6 main tables or figures for Articles, with supplementary figures handled separately. Treat that as a combined display-item cap, not as 6 figures plus separate main tables.

Figure requirements:

• Accepted graphics file types for revised manuscripts: eps, tiff, ai, psd, png, or ps (PowerPoint files are discouraged); pdf and jpg are accepted for initial submissions only; color images should be supplied in RGB

• Single-column graph width is 7.94 cm (3.125 in); at that size, text in the graph must be no smaller than 6 pt and no larger than 12 pt, and drawn lines must be at least 0.5 point thick

• Each figure needs a legend with a short title sentence and a description; legends must include the number of technical and biological replicates

• Figures must be cited and numbered in the order they appear in the text

• Reports of randomized controlled trials should follow the CONSORT guidelines

Table formatting:

• Number tables with Arabic numerals and mark footnotes with lower-case letters (a, b, c)

• Every column must have a header

• AACR does not prescribe these two, but we suggest following standard oncology conventions in patient demographic tables (median age with range, percentages for categorical variables) and reporting hazard ratios with 95% confidence intervals

• Complex or large tables should be uploaded as tabular supplementary data (xlsx or csv), and tables should not be included as part of a figure

Supplementary Data:

Clinical Cancer Research accepts supplementary figures, tables, and data files. Each item must be cited in the main text, and AACR subjects supplementary data to the same peer review standards. AACR says the article must stand on its own without the supplementary data and that additional text, such as supplementary results or discussion, is not acceptable.

Clinical Cancer Research uses the same AACR reference format as Cancer Research. AACR numbers references in the order of their first mention in the text and asks authors to cite only the number assigned to the reference. Its instructions do not say whether that number goes in parentheses or in superscript, and they state that a manuscript's references need not be formatted according to journal style before submission.

Reference list formatting:

• Numbered in order of first mention in the text

• More than 6 authors: list the first 6, followed by "et al."; 6 or fewer authors: list all of them

• Journal titles are abbreviated in AACR's examples (for example, N Engl J Med)

• Year after journal abbreviation

• Inclusive page numbers abbreviated (AACR's example shows 1385-93)

Worked example (AACR style, with the common wrong form shown for contrast):

Correct (AACR): Zhang Y, Liu T, Chen W, Patel SR. Circulating tumor DNA as a predictive biomarker for immunotherapy response in non-small cell lung cancer. *Clin Cancer Res* 2026;**32**:456-64.
Wrong (Vancouver/APA preset most reference managers default to): Zhang, Y., Liu, T., Chen, W., & Patel, S. R. (2026). Circulating tumor DNA as a predictive biomarker.

Clinical Cancer Research, 32, 456-464.

The difference is what trips auto-exported bibliographies: AACR writes "Zhang Y" with no comma or period inside the name, abbreviates the journal name, places the year after the abbreviation, and uses inclusive page numbers (456-64, not 456-464); the Vancouver/APA form your reference manager exports by default uses "Zhang, Y." and is wrong for Clinical Cancer Research.

Example clinical trial citation (AACR):

2. Garcia ML, Thompson RK, Williams JK, Anderson PH, Brown CD, Davis SE, et al. Phase II trial of neoadjuvant pembrolizumab plus chemotherapy in triple-negative breast cancer: final analysis. *Clin Cancer Res* 2026;**32**:1023-35.

AACR says references need not be formatted according to journal style before submission, so the reference style matters most when you prepare a revised or final manuscript. If you're accustomed to the output styles of Nature, Cell, or NEJM, you'll need to switch your reference manager output style specifically to AACR at that point.

AACR lists Word (doc, docx) and Rich Text Format as manuscript file types, with pdf accepted for initial submissions only.

Word or PDF submissions:

• Use AACR's author instructions and article-style page as the starter checklist

• 12-point Arial, Helvetica, or Times New Roman font (AACR FAQ)

• Pages and/or lines numbered

• Title page as first page

• Initial submission: figures may sit next to their legends in the manuscript file; revised submission: figures must be uploaded as separate source files and may not be in the same file as the main text

LaTeX:

• AACR's list of acceptable manuscript file types does not include LaTeX source files

• For a revised manuscript, AACR asks for Word or RTF source files for the text and separate graphics files for the figures

1. Translational Relevance is required. AACR lists the statement as required for Research Articles and Research Briefs, so a missing or vague one is a clear gap in the submission. If your study is purely basic biology with no clear translational angle, it probably belongs in Cancer Research instead.

2. Clinical trial reporting standards. AACR asks reports of randomized controlled trials to follow CONSORT guidelines, observational studies STROBE, meta-analyses and systematic reviews PRISMA, and diagnostic accuracy studies STARD. AACR requires every clinical trial to be registered in a primary or partner registry of the WHO Registry Network at or before the start of enrollment, and asks for the registration number whenever a trial is mentioned in the text.

3. Biomarker studies have specific expectations. Clinical Cancer Research is one of the top venues for biomarker discovery and validation. The editors expect biomarker studies to follow the REMARK guidelines (Reporting Recommendations for Tumor Marker Prognostic Studies). Discovery-only biomarker studies without any validation cohort face a steep uphill battle.

4. Patient consent and ethics. Manuscripts reporting human experimentation must include a statement of the ethical guidelines followed, a statement of institutional review board approval where appropriate, and a statement that informed written consent was obtained from each participant. If the IRB determined consent was unnecessary, include an explanatory statement in the manuscript.

5. Methods subheadings. AACR asks for a Statistical Analysis subsection whenever statistical analysis is performed and a Data Availability subsection at the end of the Materials and Methods. We suggest purpose-driven subheadings such as "Patient Selection and Treatment" and "Biomarker Analysis," and advise against vague ones like "Methods Part 1."

6. Pharmacokinetic and pharmacodynamic data. PK/PD studies should include standard noncompartmental or compartmental analysis parameters (Cmax, AUC, t1/2) in tables with appropriate units. NONMEM or similar modeling software should be cited with version numbers.

A Clinical Cancer Research Article follows this structure:

Results and Discussion must be separate sections (combined format is not accepted). The Introduction should be concise. AACR asks the Discussion to interpret the data concisely without repeating the Results; well-founded speculation and discussion of the wider implications of the findings are welcome.

For manuscripts targeting Clinical Cancer Research, four patterns generate the most consistent desk-rejection outcomes.

Structured abstract uses headings that do not match the journal's pattern. AACR lists a 250-word structured abstract for Articles and Research Briefs and does not name the headings. Abstracts in recent published articles use Purpose, Experimental Design (or Patients and Methods for clinical studies), Results, and Conclusions, so generic headings such as Background and Methods make a submission look unfamiliar with the journal.

Translational relevance section absent or too vague. CCR requires a Translational Relevance statement of 120 to 150 words describing how the results might be applied to the future practice of cancer medicine. A statement that merely restates the abstract, without specifying a clinical path (mechanism-to-drug-target, biomarker-to-trial, or pathway-to-treatment-strategy), leaves the one journal-specific element of the manuscript empty.

Clinical data without clear endpoint and reporting standards. AACR asks randomized trials to follow CONSORT and observational studies STROBE, and asks clinical trial manuscripts to state the primary objective, eligibility criteria, measured endpoints, and statistical approach. Papers reporting clinical outcomes without specifying the response and toxicity criteria used (for example RECIST and CTCAE) leave reviewers unable to judge the result.

Scope is basic cancer biology without clinical translation link. Despite the broad scope of AACR, CCR is specifically a translational medicine journal. Papers that present basic mechanistic findings in cell lines or mouse models without a direct clinical application pathway, a biomarker hypothesis, or a patient tissue validation component are desk-rejected.

The journal's About page describes its scope as "innovative clinical and translational cancer research studies that bridge the laboratory and the clinic." In our pre-submission review work, the Translational Relevance statement is the place this is decided: when it merely restates the abstract instead of naming a concrete clinical path, the editor reads the whole package as basic biology with a thin clinical paragraph attached, and the paper is returned before review.

A Clinical Cancer Research submission readiness check evaluates manuscript scope, AACR abstract format, and translational relevance against these desk-rejection patterns before you submit.